Innovative Plant-Based Medicine Set to Transform Inflammatory Disease Treatments in the US Market
LONDON, March 22, 2023 /PRNewswire/ -- MGC Pharmaceuticals Ltd. (LSE:MXC.LN), (AMEX:MXC), (OTC:MGCLF), a European based bio-pharma company specializing in the development and supply of affordable, ethically produced plant-inspired medicines, announces that its innovative product ArtemiC™ has recently been listed as an over-the-counter (OTC) drug in the USA on the FDA National Drug Code (NDC) Database under the code 83278. Facilitated by the company's US-based supply and distribution partner, AMCPharma USA, LLC. (AMC), ArtemiC™ will be available in US Pharmacy Benefit Management (PBM) networks starting April 2023, with ongoing discussions for its inclusion in other independent outlets.
Read more at prnewswire.com